What this Trial Is About

Researchers are investigating the long-term effects of pneumonia on cardiovascular and respiratory diseases within the HOMI-LUNG project, funded by Horizon Europe. This international project focuses on understanding how respiratory infections like pneumonia may lead to worsening heart and lung conditions. It aims to measure the impact of cardiovascular disease after pneumonia, explore patients' acceptance of lasting health changes, and identify pneumonia subtypes linked to worsening cardiovascular disease. The study involves collecting blood samples and oropharyngeal swabs at several times: at the start, 6 months, 18 months, and 30 months, with some groups having fewer samples. Participants undergo various tests including ECGs at the same intervals, and assessments of respiratory and heart function through exercise tests, spirometry, plethysmography, and carbon monoxide absorption tests at the start, 6 months, and 30 months. A CT scan to measure calcium in arteries is performed at 30 months to evaluate individual cardiovascular risk. Participants will be monitored over 30 months with repeated clinical evaluations and laboratory tests to track changes in heart and lung health. Outcomes measured include major adverse cardiovascular events within 6 months and poor cardiorespiratory fitness after 30 months. The study involves detailed assessments to understand disease progression and long-term health alterations after pneumonia, ensuring safety and comprehensive follow-up throughout the participation period.

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia